Obeticholic acid for the treatment of primary biliary cirrhosis

References

• Liaskou E, Hirschfield GM, Gershwin ME. Mechanisms of tissue injury in autoimmune liver diseases. Semin Immunopathol. 2014;36(5):553–568
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol. 2013;8:303–330
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterol. 2010;139(5):1481–1496
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Gershwin ME. Primary biliary cirrhosis: one disease with many faces. Isr Med Assoc J. 2011;13(1):55–59
   PubMed Web of Science ®Google Scholar
• Katsumi T, Tomita K, Leung PSC, et al. Animal models of primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48(2–3):142–153
   PubMed Web of Science ®Google Scholar
• Wang Y-H, Yang W, Yang J-B, et al. Systems biologic analysis of T regulatory cells genetic pathways in murine primary biliary cirrhosis. J Autoimmun. 2015;59:26–37
   PubMed Web of Science ®Google Scholar
• Floreani A, Franceschet I, Perini L, et al. New therapies for primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48(2–3):263–272
   PubMed Web of Science ®Google Scholar
• Yao Y, Yang W, Yang Y-Q, et al. Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2Rα(-/-) mice. J Autoimmun. 2014;51:99–108
   PubMed Web of Science ®Google Scholar
• Huang W, Kachapati K, Adams D, et al. Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cellsAutoimmun. 2014;50:123–134
   Web of Science ®Google Scholar
• Gohlke H, Schmitz B, Sommerfeld A, et al. α5 β1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes. Hepatology. 2013;57(3):1117–1129
   PubMed Web of Science ®Google Scholar
• Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(6):318–328
   PubMedGoogle Scholar
• Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterol. 2005;128(2):297–303
   PubMed Web of Science ®Google Scholar
• Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 2006;130(3):715–720
   PubMed Web of Science ®Google Scholar
• Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871–877
   PubMed Web of Science ®Google Scholar
• Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55(6):1361–1367
   PubMed Web of Science ®Google Scholar
• Kuiper EMM, Hansen BE, de Vries RA, et al. Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid. Gastroenterology. 2009;136(4):1281–1287
   PubMed Web of Science ®Google Scholar
• Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105(10):2186–2194
   PubMed Web of Science ®Google Scholar
• Trivedi PJ, Bruns T, Cheung A, et al. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. J Hepatol. 2014;60(6):1249–1258
   PubMed Web of Science ®Google Scholar
• Carbone M, Sharp SJ, Flack S, et al. The UK-PBC Risk Scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis. Hepatology. 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology. 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Schaap FG, Trauner M, Jansen PLM. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2014;11(1):55–67
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45(17):3569–3572
   PubMed Web of Science ®Google Scholar
• Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60(4):463–472
   PubMed Web of Science ®Google Scholar
• Naugler WE, Tarlow BD, Fedorov LM, et al. Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers. Gastroenterology. 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Verbeke L, Farre R, Trebicka J, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2014;59(6):2286–2298
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Mason A, Luketic V, et al. Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. Gastroenterology. 2015;148(4):751–761
   PubMed Web of Science ®Google Scholar
• Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50(1):291–308
   PubMed Web of Science ®Google Scholar
• Lleo A, Oertelt-Prigione S, Bianchi I, et al. Y chromosome loss in male patients with primary biliary cirrhosis. J Autoimmun. 2013;41:87–91
   PubMed Web of Science ®Google Scholar
• Hirschfield GM. Diagnosis of primary biliary cirrhosis. Best Practice & Research Clinical Gastroenterology. 2011;25(6):701–712
   PubMed Web of Science ®Google Scholar
• Mells GF, Pells G, Newton JL, et al. Impact of primary biliary cirrhosis on perceived quality of life: The UK-PBC national study. Hepatology. 2013;58(1):273–283
   PubMed Web of Science ®Google Scholar
• Dyson JK, Webb G, Hirschfield GM, et al. Unmet clinical need in autoimmune liver diseases. J Hepatol. 2015;62(1):208–218
   PubMed Web of Science ®Google Scholar
• Bassendine MF. Primary biliary cirrhosis. In: Warrell DA, Cox TM, Firth JD, editors. Oxford textbook of medicine. Oxford: Oxford University Press, 2010; p. 2465–2468
   Google Scholar
• Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002;123(4):1044–1051
   PubMed Web of Science ®Google Scholar
• Christensen E, Crowe J, Doniach D, et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology. 1980;78(2):236–246
   PubMed Web of Science ®Google Scholar
• Locke GRTherneau TM, Ludwig J, et al. Time course of histological progression in primary biliary cirrhosis. Hepatology. 1996;23(1):52–56
   PubMed Web of Science ®Google Scholar
• EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–267
   PubMed Web of Science ®Google Scholar
• Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic Acid. Gastroenterology. 2013;144(3):560–569
   PubMed Web of Science ®Google Scholar
• Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;147(6):1338–1349
   PubMed Web of Science ®Google Scholar
• Trivedi PJ, Kumagi T, Harthy N Al, et al. Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2014;12(7):1179–1185
   PubMed Web of Science ®Google Scholar
• Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet. 1999;354(9184):1053–1060
   PubMed Web of Science ®Google Scholar
• Rudic JS, Poropat G, Krstic MN, et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;12:CD000551
   PubMedGoogle Scholar
• Corpechot C, Carrat F, Poupon R, Poupon R-E. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology. 2002;122(3):652–658
   PubMed Web of Science ®Google Scholar
• Jones DE, Rifai A Al, Frith J, et al. The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up. J Hepatol. 2010;53(5):911–917
   PubMed Web of Science ®Google Scholar
• Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut. 1979;20(2):137–140
   PubMed Web of Science ®Google Scholar
• Folseraas T, Liaskou E, Anderson CA, Karlsen TH. Genetics in PSC: what do the “risk genes” teach us? Clin Rev Allergy Immunol. 2014;48(2–3):154–164
   Web of Science ®Google Scholar
• Sun Y, Haapanen K, Li B, et al. Women and primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48(2–3):285–300
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Siminovitch KA, Genetics in PBC. What Do the “Risk Genes” Teach Us? Clinical Reviews in Allergy & Immunology. 2014;48(2–3):176–181
   Web of Science ®Google Scholar
• Paumgartner G. Pharmacotherapy of cholestatic liver diseases. J Dig Dis. 2010;11(3):119–125
   PubMed Web of Science ®Google Scholar
• Hohenester S, Wenniger LM de B, Paulusma CC, et al. A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology. 2012;55(1):173–183
   PubMed Web of Science ®Google Scholar
• Ballatori N, Christian WV, Lee JY, et al. OSTα-OSTβ: A major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology. 2005;42(6):1270–1279
   PubMed Web of Science ®Google Scholar
• Medina JF, Martínez-Ansó null, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology. 1997;25(1):12–17
   PubMed Web of Science ®Google Scholar
• Prieto J, García N, Martí-Climent JM, et al. Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology. 1999;117(1):167–172
   PubMed Web of Science ®Google Scholar
• Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. J Hepatol. 2015;62(Suppl 1):S25–S37
   Google Scholar
• Rodrigues CM, Steer CJ. The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent. Expert Opin Investig Drugs. 2001;10(7):1243–1253
   PubMed Web of Science ®Google Scholar
• Zollner G, Fickert P, Zenz R, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology. 2001;33(3):633–646
   PubMed Web of Science ®Google Scholar
• Takeyama Y, Kanegae K, Inomata S, et al. Sustained upregulation of sodium taurocholate cotransporting polypeptide and bile salt export pump and downregulation of cholesterol 7α-hydroxylase in the liver of patients with end-stage primary biliary cirrhosis. Med Mol Morphol. 2010;43(3):134–138
   PubMed Web of Science ®Google Scholar
• Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6(3):517–526
   PubMed Web of Science ®Google Scholar
• Marschall H, Wagner M, Zollner G, et al. Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans. Gastroenterology. 2005;129(2):476–485
   PubMed Web of Science ®Google Scholar
• Ananthanarayanan M, Balasubramanian N, Makishima M, et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem. 2001;276(31):28857–28865
   PubMed Web of Science ®Google Scholar
• Boyer JL, Trauner M, Mennone A, et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol. 2006;290(6):G1124–G1130
   PubMed Web of Science ®Google Scholar
• Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2(4):217–225
   PubMed Web of Science ®Google Scholar
• Kir S, Beddow SA, Samuel VT, et al. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science. 2011;331(6024):1621–1624
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–965
   PubMed Web of Science ®Google Scholar
• Huang L, Zhao A, Lew J-L, et al.Farnesoid X. Receptor Activates Transcription of the Phospholipid Pump MDR3. J Biol Chem. 2003;278(51):51085–51090
   PubMed Web of Science ®Google Scholar
• Sinal CJ, Tohkin M, Miyata M, et al. Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis. Cell. 2000;102(6):731–744
   PubMed Web of Science ®Google Scholar
• Ghonem NS, Ananthanarayanan M, Soroka CJ, Boyer JL. Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology. 2014;59(3):1030–1042
   PubMed Web of Science ®Google Scholar
• Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology. 2015;62(2):635–643
   PubMed Web of Science ®Google Scholar
• Kok T, Hulzebos CV, Wolters H, et al. Enterohepatic Circulation of Bile Salts in Farnesoid X Receptor-deficient Mice Efficient Intestinal Bile Salt Absorption in the Absence of Ileal Bile Acid-Binding Protein. J Biol Chem. 2003;278(43):41930–41637
   PubMed Web of Science ®Google Scholar
• Kim I, Ahn S-H, Inagaki T, et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res. 2007;48(12):2664–2672
   PubMed Web of Science ®Google Scholar
• Modica S, Petruzzelli M, Bellafante E, et al. Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis. Gastroenterology. 2012;142(2):355–365
   PubMed Web of Science ®Google Scholar
• Liu Y, Binz J, Numerick MJ, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest. 2003;112(11):1678–1687
   PubMed Web of Science ®Google Scholar
• Uriarte I, Fernandez-Barrena MG, Monte MJ, et al. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut. 2013;62(6):899–910
   PubMed Web of Science ®Google Scholar
• Kim I, Morimura K, Shah Y, et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis. 2007;28(5):940–946
   PubMed Web of Science ®Google Scholar
• Mencarelli A, Renga B, Migliorati M, et al. The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis. J Immunol. 2009;183(10):6657–6666
   PubMed Web of Science ®Google Scholar
• Wang Y-D, Chen W-D, Wang M, et al. Farnesoid X receptor antagonizes NF-κB in hepatic inflammatory response. Hepatology. 2008;48(5):1632–1643
   PubMed Web of Science ®Google Scholar
• Yang F, Huang X, Yi T, et al. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007;67(3):863–867
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology. 2004;127(5):1497–1512
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Rizzo G, Antonelli E, et al. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther. 2005;314(2):584–595
   PubMed Web of Science ®Google Scholar
• Lee FY, Kast-Woelbern HR, Chang J, et al. Alpha-crystallin is a target gene of the farnesoid X-activated receptor in human livers. J Biol Chem. 2005;280(36):31792–31800
   PubMed Web of Science ®Google Scholar
• Fickert P, Fuchsbichler A, Moustafa T, et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol. 2009;175(6):2392–2405
   PubMed Web of Science ®Google Scholar
• Li J, Kuruba R, Wilson A, et al. Inhibition of Endothelin-1-Mediated Contraction of Hepatic Stellate Cells by FXR Ligand. PLoS One. 2010;5(11):e13955
   PubMed Web of Science ®Google Scholar
• Huet P-M, Vincent C, Deslaurier J, et al. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterol. 2008;135(5):1552–1560
   PubMed Web of Science ®Google Scholar
• Patanwala I, McMeekin P, Walters R, et al. A validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score. J Hepatol. 2013;59(2):327–335
   PubMed Web of Science ®Google Scholar
• Crosignani A, Setchell KD, Invernizzi P, et al. Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet. 1996;30(5):333–358
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Jones D, Luketic V, et al. An international study evaluating the farsenoid X receptor agonist obeticholic acid as monotherapy in PBC. J Hepatol. 2011;54:S13
   Web of Science ®Google Scholar
• Nevens F, Andreone P, Mazzella G, et al. The First Primary Biliary Cirrhosis (PBC) Phase 3 Trial in Two Decades – an International Study of the FXR Agonist Obeticholic Acid in PBC Patients. J Hepatol. 2014;60(1):S525–S526
   Google Scholar
• Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review. J Hepatol. 2012;56(5):1181–1188
   PubMed Web of Science ®Google Scholar
• Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012;56(1):198–208
   PubMed Web of Science ®Google Scholar
• Keitel V, Ullmer C, Häussinger D. The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol Chem. 2010;391(7):785–789
   PubMed Web of Science ®Google Scholar
• Alemi F, Kwon E, Poole DP, et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest. 2013;123(4):1513–1530
   PubMed Web of Science ®Google Scholar
• Lieu T, Jayaweera G, Zhao P, et al. The Bile Acid Receptor TGR5 Activates the TRPA1 Channel to Induce Itch in Mice. Gastroenterology. 2014;147(6):1417–1428
   PubMed Web of Science ®Google Scholar
• Quist RG, Ton-Nu HT, Lillienau J, et al. Activation of mast cells by bile acids. Gastroenterology. 1991;101(2):446–456
   PubMed Web of Science ®Google Scholar
• Beuers U, Kremer AE, Bolier R, Elferink RPJO. Pruritus in cholestasis: facts and fiction. Hepatology. 2014;60(1):399–407
   PubMed Web of Science ®Google Scholar
• Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review. Atherosclerosis. 2007;194(2):293–299
   PubMed Web of Science ®Google Scholar
• Hambruch E, Miyazaki-Anzai S, Hahn U, et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. J Pharmacol Exp Ther. 2012;343(3):556–567
   PubMed Web of Science ®Google Scholar
• Mencarelli A, Renga B, Distrutti E, Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol. 2009;296(2):H272–H281
   PubMed Web of Science ®Google Scholar
• Calkin AC, Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol. 2012;13(4):213–224
   PubMed Web of Science ®Google Scholar
• de Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013;17(5):657–669
   PubMed Web of Science ®Google Scholar
• Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nuclear receptor signaling. 2010;8:e005
   Google Scholar
• Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases. J Lipid Res. 2012;53(9):1723–1737
   PubMed Web of Science ®Google Scholar
• Degirolamo C, Modica S, Vacca M, et al. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor–null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology. 2015;61(1):161–170
   PubMed Web of Science ®Google Scholar
• Nicholes K, Guillet S, Tomlinson E, et al. A mouse model of hepatocellular carcinoma. Am J Pathol. 2002;160(6):2295–2307
   PubMed Web of Science ®Google Scholar
• Lin BC, Desnoyers LR. FGF19 and cancer. Adv Exp Med Biol. 2012;728:183–194
   PubMed Web of Science ®Google Scholar
• Ahn S-M, Jang SJ, Shim JH, et al. Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification. Hepatology. 2014;60(6):1972–1982
   PubMed Web of Science ®Google Scholar
• Trivedi PJ, Lammers WJ, van Buuren HR, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. 2015
   PubMed Web of Science ®Google Scholar
• Wu X, Ge H, Lemon B, et al. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc Natl Acad Sci USA. 2010;107(32):14158–14163
   PubMed Web of Science ®Google Scholar
• Grigorian AY, Mardini HE, Corpechot C, et al. Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39(3):296–306
   PubMed Web of Science ®Google Scholar
• Lens S, Leoz M, Nazal L, et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int. 2014;34(2):197–203
   PubMed Web of Science ®Google Scholar
• Hosonuma K, Sato K, Yamazaki Y, et al. A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia. Am J Gastroenterol. 2015;110(3):423–431
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Gershwin ME. New therapeutics in primary biliary cirrhosis: will there ever be light? Liver Int. 2014;34(2):167–170
   PubMed Web of Science ®Google Scholar
• Tanaka H, Yang G-X, Iwakoshi N, et al. Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. Clin Exp Immunol. 2013;174(3):364–371
   PubMed Web of Science ®Google Scholar
• Hudspeth K, Pontarini E, Tentorio P, et al. Therole of natural killer cells in autoimmune liver disease: A comprehensive review. J Autoimmun. 2013;46:55–65
   PubMed Web of Science ®Google Scholar
• Beuers U, Gershwin ME. Unmet challenges in immune-mediated hepatobiliary diseases. Clin Rev Allergy Immunol. 2015;48(2–3):127–131
   PubMed Web of Science ®Google Scholar
• Trivedi PJ, Hirschfield GM. Treatment of autoimmune liver disease: current and future therapeutic options. Ther Adv Chronic Dis. 2013;4(3):119–141
   PubMedGoogle Scholar
• Baghdasaryan A, Claudel T, Gumhold J, et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO-3 output. Hepatology. 2011;54(4):1303–1312
   PubMed Web of Science ®Google Scholar
• Parés A. Old and novel therapies for primary biliary cirrhosis. Semin Liver Dis. 2014;34(3):341–351
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang W, Leung PSC, et al. Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology. 2014;60(5):1708–1716
   PubMed Web of Science ®Google Scholar
• Chen RCY, Naiyanetr P, Shu S-A, et al. Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology. 2013;57(4):1498–1508
   PubMed Web of Science ®Google Scholar
• Dhirapong A, Yang G-X, Nadler S, et al. Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology. 2013;57(2):708–715
   PubMed Web of Science ®Google Scholar
• Yang C-Y, Ma X, Tsuneyama K, et al. IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology. 2014;59(5):1944–1953
   PubMed Web of Science ®Google Scholar
• van Dijk R, Beuers U, Bosma PJ. Gene replacement therapy for genetic hepatocellular jaundice. Clin Rev Allergy Immunol. 2015;48(2–3):243–253
   PubMed Web of Science ®Google Scholar